Literature DB >> 23229813

Tiotropium Respimat increases the risk of mortality.

Christine R Jenkins, Richard Beasley.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 23229813     DOI: 10.1136/thoraxjnl-2012-202482

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  6 in total

Review 1.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

Review 2.  Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.

Authors:  Ralph J Panos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-04-30

3.  Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.

Authors:  Francesco Trotta; Roberto Da Cas; Maja Rajevic; Mariangela Rossi; Giuseppe Traversa
Journal:  BMJ Open       Date:  2015-05-25       Impact factor: 2.692

4.  The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods.

Authors:  Peter Kardos; Claus Vogelmeier; Roland Buhl; Carl-Peter Criée; Heinrich Worth
Journal:  BMC Pulm Med       Date:  2015-01-12       Impact factor: 3.317

Review 5.  Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma.

Authors:  Alcibey Alvarado-Gonzalez; Isabel Arce
Journal:  J Clin Med Res       Date:  2015-09-25

6.  Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study.

Authors:  Francesco Trotta; Stefania Spila-Alegiani; Roberto Da Cas; Maja Rajevic; Valentino Conti; Mauro Venegoni; Mariangela Rossi; Giuseppe Traversa
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.